Journal Club - Tirzepatide may lead weight loss of up to 23 percent in obese people
Advertisement
Recent data from SURMOUNT-1 clinical trial showed that tirzepatide achieved superior weight loss compared to a placebo in obese/overweight individuals at 72 weeks of treatment. According to the findings, the individuals lost up to 22.2% of their body weight (52 lb.).
Tirzepatide is a novel once-weekly glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. The results were reported by the pharmaceutical company Eli Lilly and Company.
For more details check out the full story on the link below:
Tirzepatide May Lead Weight Loss Of Up To 23 Percent In Obese People: SURMOUNT-1 Trial
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.